---
layout: post
title: "Classification Categories for Certain Supplements Under the Biosimilar User Fee Amendments of 2022; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:56:26 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-17262
original_published: 2023-08-11 00:00:00 +0000
significance: 8.00
---

# Classification Categories for Certain Supplements Under the Biosimilar User Fee Amendments of 2022; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 11, 2023 00:00 UTC
**Document Number:** 2023-17262

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Classification Categories for Certain Supplements Under BsUFA III." This draft guidance provides recommendations for applicants and FDA review staff on classification categories A, B, C, D, E, and F for original and resubmitted prior approval supplements submitted to approved applications under the Public Health Service Act (PHS Act). The commitment letter associated with the Biosimilar User Fee Amendments of 2022 (BsUFA III) sets forth these supplement classification categories and their associated review performance goals. This draft guidance is intended to help applicants identify the appropriate classification category and review goal date of the supplement being submitted.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/11/2023-17262/classification-categories-for-certain-supplements-under-the-biosimilar-user-fee-amendments-of-2022)
- API: https://www.federalregister.gov/api/v1/documents/2023-17262

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
